BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients

Summary by AI BETAClose X

BioNTech and OncoC4 announced updated data from the PRESERVE-003 Phase 3 trial showing gotistobart nearly doubled median overall survival in previously treated squamous non-small cell lung cancer patients, reaching 18.5 months compared to 10.0 months with standard-of-care chemotherapy. This investigational immunomodulator, which targets CTLA-4 to deplete regulatory T cells in the tumor microenvironment, demonstrated a manageable safety profile with grade ≥3 treatment-related adverse events in 44.4% of patients receiving gotistobart versus 48.8% receiving docetaxel. These encouraging results, presented at the IASLC 2026 World Conference on Lung Cancer, suggest gotistobart's potential to significantly improve outcomes in a patient population with limited treatment options.

Disclaimer*

UK 100

Latest directors dealings